TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28364426
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) alone
Study: 28364426
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) combined with zolpidem as needed
Study: 25594222
Drug: 3-hour oral
Normalized name: nitroglycerin 0.3 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour oral glucose tolerance test (OGTT) values (fasting, 1-hour, 2-hour, and 3-hour)
Study: 25594222
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose between 85 and 94 mg/dL
Study: 25594222
Drug: Fasting OGTT
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting OGTT < 95 mg/dL
Study: 21872979
Drug: β‐Blocker therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐Blocker therapy in patients without IHD
Study: 18068613
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional drug)
Study: 29437243
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment
Study: 9649984
Drug: Epidural midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 5 mL saline (Group B)
Study: 9649984
Drug: Epidural midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 10 mL saline (Group C)
Study: 9649984
Drug: Epidural midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 15 mL saline (Group D)
Study: 9649984
Drug: Epidural midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 3 mL saline (Group A)
Study: 25591873
Drug: Diazoxide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (7 mg/kg)
Study: 20729034
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution inflated cuffs
Study: 15671432
Drug: Calfactant (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calfactant (2 doses of 80 mL/m2)
Study: 29682995
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isosorbide dinitrate spray and chitosan gel
Study: 18319224
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate spray
Study: 29145771
Drug: Chitosan gel
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan gel
Study: 23110494
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg) biannually
Study: 21050332
Drug: Structured reminiscence
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured reminiscence protocol offered twice weekly for 6 weeks
Study: 17379055
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Study: 15682350
Drug: TPV 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV 250 mg to 1250 mg twice daily for 11 days followed by RTV 100 mg for 21 days
Study: 15682350
Drug: TPV 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV 500 mg and 750 mg with RTV 100 mg or 200 mg
Study: 10623704
Drug: 5‐day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) with l‐OHP (125 mg/m(2), as a 6‐hour infusion)
Study: 10623704
Drug: 5‐day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) without l‐OHP
Study: 1337070
Drug: Azithromycin, 250
Normalized name: Azithromycin, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 250 mg bd for 2 days followed by 250 mg od for 8 days
Study: 1337070
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg bd for 14 days
Study: 29061617
Drug: HEART score
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEART score calculation by physicians in daily practice
Study: 19553404
Drug: Doripenem 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 1000 mg infused over 4 hours
Study: 18225515
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using Photosens (aluminum phthalocyanine) intravenously injected at a dose of 0.05 mg/kg, with laser irradiation at 675 nm and exposure light dose of 120 J/cm2, total light dose not greater than 500 J/cm2.
Study: 18225515
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (control group).
Study: 15066462
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d orally)
Study: 9571510
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency ultrasound treatment, started immediately after plaster removal
Study: 2834976
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without acebutolol treatment
Study: 28104641
Drug: Volumetric CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric CT dose index
Study: 26414587
Drug: Oral ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ginger for the first three days of the chemotherapy cycle (n = 30)
Study: 19627223
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (health information brochures, a list of community resources, and a monthly telephone call to confirm contact information)
Study: 16680254
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV at surgical skin closure
Study: 16680254
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg IV immediately after anesthesia induction
Study: 17179250
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV
Study: 12088975
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg IV
Study: 18450829
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg
Study: 30265350
Drug: Manganese nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 100 mg/kg
Study: 30265350
Drug: Manganese nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 50 mg/kg
Study: 30265350
Drug: Manganese nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 10 mg/kg
Study: 30265350
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of Mn supplementation from 100 mg/kg to 50 or 10 mg/kg
Study: 29628593
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg diluted in 20 mL normal saline (NS) over 10 min
Study: 29628593
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) infusion of 20 mL over 10 min (Control Group)
Study: 26661403
Drug: FEC (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2, day 1, every 3 weeks)
Study: 26661403
Drug: EP (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, day 1, every 3 weeks)
Study: 10803490
Drug: Diltiazem-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-based treatment strategy
Study: 7546987
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term oral anticoagulant treatment
Study: 31048181
Drug: Grape byproduct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape byproduct (0; 100; 200; and 300 g/kg DM)
Study: 27854065
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders for the first 2 weeks, then once weekly thereafter for 3 months.
Study: 22248554
Drug: Front-only suspension
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-only suspension (FS)
Study: 22248554
Drug: Front-and-rear suspension
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-and-rear suspension (FRS)
Study: 19679248
Drug: Amlodipine-based therapy
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based therapy
Study: 17288679
Drug: Atenolol-based therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based therapy
Study: 11246536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients with total cholesterol > 5.2 mmol/L taking low-dose aspirin)
Study: 9728805
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific regimen not detailed), evaluated at baseline, 7 days, 14 days, and 25 days post-treatment.
Study: 9728805
Drug: Pre-treatment values
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment values of Hb < or = 9 g/dl in leukemia patients.
Study: 10806134
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg)
Study: 9799042
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg)
Study: 7995007
Drug: Enalapril during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril during angiotensin II infusion
Study: 7995007
Drug: Lisinopril during
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril during angiotensin II infusion
Study: 5356549
Drug: Concurrent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent infusion of amino-acids and hormones (secretin and pancreozymin)
Study: 5356549
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of amino-acids or hormones individually
Study: 29548608
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccine (TIV)
Study: 30947385
Drug: Oral healthcare
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral healthcare motivation intervention group
Study: 12671693
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (initial dose 150 IU kg(‐1) three times weekly)
Study: 10872533
Drug: Potato carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato carbohydrates (g)
Study: 10872533
Drug: Cereal carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal carbohydrates (g)
Study: 10872533
Drug: Fruit carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit carbohydrates (g)
Study: 10872533
Drug: Milk carbohydrates
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk carbohydrates (g)
Study: 3987788
Drug: Procyclidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procyclidine (10 mg) - intravenous administration
Study: 3987788
Drug: Procyclidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procyclidine (10 mg) - oral administration
Study: 31571412
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg orally every 6 hours for 7 days
Study: 28731373
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1% Metformin Gel (MF)
Study: 11317472
Drug: MPPG (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPPG (3 x 150 mg daily)
Study: 8496526
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release propranolol (mean 293 mg/day)
Study: 8496526
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release diltiazem (mean 350 mg/day)
Study: 8496526
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean 79 mg/day)
Study: 30380020
Drug: Extending Treatment
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extending Treatment Effectiveness of Naltrexone (EXTEND) trial
Study: 21481280
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin/Vinorelbine (PLD/VNB) - PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, cycles every 4 weeks
Study: 16414394
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser treatment with a wavelength of 810 nm
Study: 26577034
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (2 g)
Study: 25913660
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (wrist arthroscopy and percutaneous antegrade screw fixation)
Study: 21542026
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg alcohol
Study: 22841455
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of alcohol (0.4 g/kg and 0.6 g/kg)
Study: 18652273
Drug: ART (atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART (atraumatic restorative treatment) approach using Ketac‐Molar (3M ESPE) ionomer cement
Study: 8817136
Drug: Crystalloid cardioplegia
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid cardioplegia buffered with bicarbonate (St Thomas' II solution)
Study: 19114438
Drug: High-volume Dysport
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume Dysport (500 U/5 mL)
Study: 15025796
Drug: PVI 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU 300 mg/m2 daily + mitomycin-C 7 mg/m2 every 6 weeks
Study: 11561260
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine 60 microg/kg/min
Study: 8181888
Drug: oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t.i.d.)
Study: 8181888
Drug: digoxin plus
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin plus quinidine (total dose, 1350 mg)
Study: 2967304
Drug: Prednisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (50 mg/day)
Study: 26484407
Drug: Ratio of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratio of IGFBP-1 to fasting insulin
Study: 26484407
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model assessment-insulin resistance
Study: 26484407
Drug: Corrected insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected insulin release at the glucose peak (CIRgp)
Study: 16091912
Drug: 0.5% nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% nifedipine ointment (n=32) every 8 h for 8 weeks
Study: 1350407
Drug: Acitretin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Study: 1350407
Drug: Etretinate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Study: 2938614
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g day‐1) with R warfarin (15 mg)
Study: 2938614
Drug: Warfarin enantiomers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin enantiomers (15 mg) alone
Study: 26482723
Drug: S-1 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 combined with cisplatin plus concurrent chemoradiotherapy (SCCC)
Study: 26482723
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus concurrent chemoradiotherapy (CCC)
Study: 18460401
Drug: gel‐to‐foam dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel‐to‐foam dentifrice
Study: 12956346
Drug: Microabrasion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microabrasion treatment
Study: 12956346
Drug: Control slides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control slides (no treatment)
Study: 10715523
Drug: SBAS4 hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBAS4 hepatitis B vaccine
Study: 10715523
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine with alternative formulation on alum
Study: 1622916
Drug: Oral ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ritodrine (60 mg/day) in amniocentesis group
Study: 1622916
Drug: No ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ritodrine treatment in both groups
Study: 24552755
Drug: Systane Ultra
Normalized name: Systane Ultra
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane Ultra lubricant eye drops (applied twice a day for 2 weeks)
Study: 2134648
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and preoperative treatment of the neck area
Study: 23530672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without explicit pharmacotherapy curriculum)
Study: 18042559
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of ropivacaine 2 mg ml(‐1), sufentanil 0.5 microg ml(‐1), clonidine 3 microg ml(‐1), and S(+)‐ketamine 0.25 mg ml(‐1) before incision (Group 1)
Study: 18042559
Drug: Saline before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline before operation, study solution started at the end of surgery (Group 2)
Study: 21070569
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin
Study: 12964892
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin or oral tolterodine
Study: 1300436
Drug: Furosemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (mean dose 110 mg) intravenously 30 min prior to contrast injection
Study: 29704641
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP (>3 mg/l ≤ 10 mg/l) as an isolated reading
Study: 373393
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg daily)
Study: 23176887
Drug: Salbutamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2 puffs of 100 μg)
Study: 18342964
Drug: 7-days-a-week postoperative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-days-a-week postoperative continuous irradiation (p-CAIR) in oropharynx/oral cavity subset
Study: 18342964
Drug: 5-days-a-week postoperative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-days-a-week postoperative radiotherapy (CF) in oropharynx/oral cavity subset
Study: 7805271
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy for patients with moderate stroke with stenosis <50%, not on aspirin
Study: 7805271
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy for patients with single TIA, <50% stenosis, not on aspirin
Study: 7805271
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy for high-risk patients with multiple TIAs, not on aspirin, stenosis <50%
Study: 7805271
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy for high-risk patients, mild or moderate stroke, stenosis <50%, not on aspirin
Study: 1674825
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg/ml inhaled
Study: 1674825
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg/ml inhaled
Study: 30668423
Drug: Extract mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract mixture of Andrographis paniculata and Syzygium polyanthum at a dose of 900 mg/day for 8 weeks
Study: 11826593
Drug: SF6 echocontrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF6 echocontrast agent (SonoVue) 0.6 mL
Study: 11826593
Drug: SF6 echocontrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF6 echocontrast agent (SonoVue) 1.2 mL
Study: 10084096
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg min‐1 propofol
Study: 1706012
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 240 mg
Study: 1706015
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 300 mg
Study: 1706012
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 360 mg